ClinicalTrials.gov
ClinicalTrials.gov Menu

Analyses of Human Samples Collected in Clinical Trials

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00339664
Recruitment Status : Enrolling by invitation
First Posted : June 21, 2006
Last Update Posted : June 28, 2018
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

Brief Summary:

Cancer patients in clinical trials donate various human samples (e.g., serum, plasma, blood, urine, feces, bile, saliva) for research purposes.

The purpose of this study is to conduct further analyses on these existing samples from clinical trials that are being performed outside of, but in collaboration with, the National Cancer Institute.


Condition or disease
Leukemia, Myeloid Neoplasm Metastasis Leukemia, Lymphoid Prostate Cancer

Detailed Description:
Various human samples (e.g., serum, plasma, whole blood, erythrocytes, urine, feces, bile, and/or saliva) will be collected from cancer patients enrolled on approved clinical trials, in accordance with the local protocol. These trials are being conducted at outside institutions, in collaboration with the National Cancer Institute (NCI) and the samples will be sent to the NCI for pharmacological analysis, involving determination of parent drug and/or metabolite concentrations and subsequent pharmacokinetics and statistical data analysis. This study aims to further characterize the clinical pharmacokinetic behavior of select cancer therapeutics. Future collaborators will be added via the protocol amendment procedure.

Study Type : Observational
Actual Enrollment : 2569 participants
Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Pharmacological Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Study Start Date : July 2, 2003

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Drug and/or metabolite concentration [ Time Frame: Ongoing ]
    To quantitate drug and/or metabolite concentrations in human blood samples


Secondary Outcome Measures :
  1. Pharmacological behavior of agents [ Time Frame: Ongoing ]
    To characterize the clinical pharmacological behavior of agents



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 100 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Any patients entered on approved trials of cancer therapeutics or agents that are commonly administered to patients with cancer@@@
Criteria
  • INCLUSION CRITERIA:

Any patients entered on approved trials of cancer therapeutics or agents that are commonly administered to patients with cancer at institutions outside of the intramural NCI are eligible for inclusion, provided that they have consented to pharmacological analysis in the original consent form.

EXCLUSION CRITERIA:

None anticipated at this time.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00339664


Locations
United States, District of Columbia
Childrens National Medical Center
Washington, District of Columbia, United States
United States, Florida
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, United States, 33612
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
United States, Maryland
University of Maryland, Baltimore
Baltimore, Maryland, United States, 21201-1595
Johns Hopkins Medical Center
Baltimore, Maryland, United States, 21231
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States, 21231
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
United States, Minnesota
Mayo Clinic, Rochester
Rochester, Minnesota, United States, 55905
United States, Ohio
Case Western Reserve University
Cleveland, Ohio, United States, 44106-2602
United States, Pennsylvania
University of Maryland at Amish Research Clinic, Lancaster
Lancaster, Pennsylvania, United States
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Hillman Cancer Center at University of Pittsburg Cancer Institute
Pittsburgh, Pennsylvania, United States, 15261
United States, South Carolina
Hollings Cancer Center at Medical University of South Carolina
Charleston, South Carolina, United States, 29425
United States, Virginia
McGuire Veterans Administration Medical Center
Richmond, Virginia, United States, 23249
Massey Cancer Center, Virginia Commonwealth University
Richmond, Virginia, United States, 23298
Netherlands
Leiden University Medical Center
Leiden, Netherlands
Erasmus Medical Center
Rotterdam, Netherlands
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Principal Investigator: William D Figg, Pharm.D. National Cancer Institute (NCI)

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00339664     History of Changes
Obsolete Identifiers: NCT00898196
Other Study ID Numbers: 999903242
03-C-N242
First Posted: June 21, 2006    Key Record Dates
Last Update Posted: June 28, 2018
Last Verified: May 4, 2018

Keywords provided by National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ):
Pharmacokinetics
Quantify
HPLC
LC/MS
Pharmacodynamics

Additional relevant MeSH terms:
Leukemia
Neoplasm Metastasis
Leukemia, Myeloid
Leukemia, Lymphoid
Neoplasms by Histologic Type
Neoplasms
Neoplastic Processes
Pathologic Processes
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases